^
Association details:
| Biomarker: | STRN-ALK rearrangement |
|---|---|
| Cancer: | Mesothelioma |
| Drug: | Zykadia (ceritinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
STRN-ALK rearranged pediatric malignant peritoneal mesothelioma – Functional testing of 527 cancer drugs in patient-derived cancer cells
Published date:
01/30/2021
Excerpt:
FM-MPeM-01 PDCs were analyzed for the expression of STRN-ALK...Six ALK inhibitors had DSS between 15 to 20.8, with brigatinib displaying highest sensitivity (DSS 20.8), followed by ceritinib and crizotinib.
DOI:
https://doi.org/10.1016/j.tranon.2021.101027
